Technology Description
Oregon State University is seeking a licensee to develop and commercialize products based on a method for detecting a subject's oxylipin level to predict or determine the subject’s risk for or stage of coronary artery disease (CAD). This method is dependent on the inventors' discovery that the presence and number of obstructed coronary arteries may be linked to certain circulating oxylipin concentrations. Thus, measuring a subject's concentration of particular circulating oxylipins may serve as indicator of the presence or stage of CAD and provide physicians with a fast and economical way to determine a patient's risk for CAD.
Features & Benefits
Coronary artery disease usually occurs when cholesterol-containing deposits in an individual’s major blood vessels cause arterial obstruction. It is the most common cause of heart disease in the United States. Patients who may be at risk may be subject to an array of tests, including electrocardiogram, exercise stress tests, chest x-rays, cardiac catheterization, coronary angiogram, and coronary artery scans.
Patent Pending (U.S. provisional patent application)